Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.36, Bloomberg Earnings reports. The company had revenue of $28.52 million during the quarter, compared to analysts’ expectations of $26.50 million.
Shares of Akebia Therapeutics (NASDAQ:AKBA) opened at 13.95 on Thursday. The stock has a 50 day moving average of $14.19 and a 200-day moving average of $11.82. The company’s market capitalization is $255.29 million. Akebia Therapeutics has a one year low of $7.16 and a one year high of $16.54.
In other Akebia Therapeutics news, Director Muneer A. Satter bought 1,034,482 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The stock was purchased at an average cost of $14.50 per share, with a total value of $14,999,989.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.95% of the company’s stock.
A number of brokerages have recently weighed in on AKBA. UBS AG restated a “buy” rating and issued a $17.00 price objective (up from $12.00) on shares of Akebia Therapeutics in a report on Friday, May 5th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Akebia Therapeutics in a report on Tuesday, June 6th. Needham & Company LLC restated a “buy” rating and issued a $21.00 price objective (up from $18.00) on shares of Akebia Therapeutics in a report on Wednesday, May 17th. JMP Securities boosted their price objective on shares of Akebia Therapeutics from $19.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, April 26th. Finally, Zacks Investment Research lowered shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. Akebia Therapeutics currently has an average rating of “Buy” and an average target price of $19.71.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.